Purpose: To validate a clinical risk prediction score (Ammann score) to predict adverse events (AEs) in paediatric febrile neutropenia (FN). Patients and methods: Patients <16 years of age were enrolled. A risk prediction score (based on haemoglobin ! 9 g/dl, white cell count (WCC) < 0.3 G/l, platelet count <50 G/l and chemotherapy more intensive than acute lymphoblastic leukaemia maintenance therapy) was calculated and AEs were documented. Results: In total, 100 FN episodes occurred in 52 patients, male:female ratio was 1.8:1 and median age was 56 months. At reassessment, AEs occurred in 18 of 55 (45%) low-risk FN episodes (score-< 9) and 21 of 42 (55%) high-risk episodes (score !9) (sensitivity 60%, specificity 65%, positive predictive value 53%, negative predictive value 71%). Total WCC and absolute monocyte count (AMC) were significantly associated with AEs. Conclusion: This study identified total WCC and AMC as significantly associated with AEs but failed to validate the risk prediction score. Despite improvements in survival because of improved supportive care, febrile neutropenia (FN) remains one of the most common complications of chemotherapy [7, 8] .
protocol including hospital admission and intravenous antibiotics [9, 10] . Recent guidelines recommend the use of a validated scoring system to assess the risk of developing complications and to individualize patient management [9] . Despite the development of several paediatric risk assessment scores [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] , none have been internationally validated and none validated in low-to middle-income countries with a high burden of infectious diseases [8, 22] .
This prospective study aimed to validate a risk assessment score published by Ammann et al. [21] to distinguish between high-and low-risk patients, who might develop adverse events (AEs) during FN.
The Ammann score is based on a weighted score derived from four variables [haemoglobin (Hb) !9 g/dl (weight ¼ 5), white cell count (WCC) <0.3 G/L (weight ¼ 3), platelet count <50 G/L (weight ¼3) and chemotherapy more intensive than acute lymphoblastic leukaemia maintenance therapy (weight ¼ 4)]. A score of ! 9 indicates that a patient is at high risk of developing an AE with a 92% sensitivity [21] . The inclusion of an Hb ! 9 g/dl was described by Ammann et al. [21] as "seemingly counter intuitive, but it might reflect clinically important dehydration or the previous need for transfusion of packed cells". A risk prediction model would be of value in a middle-income country with resource limitations and a high burden of infectious diseases [23, 24] . Identification of a low-risk group would enable early step-down from intravenous to oral antibiotics [25] that could benefit the institution financially and reduce patient discomfort. Identification of patients at high risk of an AE would enable intensive monitoring and early recognition of complications.
P A T I E N T S A N D M E T H O D S
All patients <16 years of age, receiving chemotherapy according to standard treatment protocols (Supplementary Appendix A) at a tertiary-level paediatric oncology unit in Cape Town, South Africa, who presented with fever and neutropenia from 22 January 2014 to 22 January 2016, were prospectively enrolled in the study. Multiple episodes of FN per patient were allowed.
On presentation, a clinical assessment, full blood count, differential WCC, serum C-reactive protein (CRP), appropriate cultures and radiological examinations were performed based on the patients' clinical condition. All patients were managed according to the current standard of care protocol for FN and reassessed by the hospital paediatric oncology team within 24 h of admission. An Ammann score [21] was calculated for each FN episode, and AEs were documented until antibiotics had been stopped or neutropenia resolved. A score of ! 9 was considered high risk of developing an AE and a score of < 9 was considered as low risk.
Definitions
Fever was defined as recorded axillary temperature !38.0 C on ! 2 occasions/24 h or !38.5 C once. Neutropenia was defined as an absolute neutrophil count 0.5 G/L [21] . AE included severe medical complications (SMCs) as a result of infection (including death, complications requiring intensive care admission and acute life-threatening events), microbiologically defined infection (MDI-positive bacterial/fungal culture from a normally sterile body compartment or the detection of a viral antigen or product of polymerase chain reaction by a validated microbiological method) and radiologically confirmed pneumonia (RCP-the presence of clinical symptoms and radiographic changes suggestive of a pneumonia as reported by a paediatric pulmonologist).
Statistical analysis
One-way analysis of variance was used to test for differences in means of continuous measurements between the AE and no AE groups. Summary statistics were reported as medians and interquartile ranges. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated from cross-tabulations between the AEs and non-AE groups and the risk score groups. A significance level was set at p < 0.05. The performance of the risk assessment tool at reassessment was calculated according to the calculation used by Ammann et al.
(sensitivity combined ¼ proportion known þ sensitivity predicted * (1Àproportion known ) [21] . The calculation was not applied at presentation as none of the episodes were excluded.
R E S U L T S

Epidemiology and description of FN episodes
Within the 2-year study period, 100 episodes of FN were reported in 52 patients [median 2 episodes (range 1-5); median patient age 56 months (range 8-175 months), male:female ratio (1.8:1). In total, >18% FN episodes were enrolled in the second year of the study, probably because of the increased number of newly diagnosed childhood malignancies (2015 n ¼ 73; 2014 n ¼ 56). The study population included 28 haematological malignancies (54% FN episodes) and 24 solid tumours (46% FN episodes) ( Table 1) .
In total, 24% FN episodes occurred in patients with advanced stage disease ( Table 1 ) and 18% had !1 underlying comorbidity (Table 2) . A clinical site of infection at presentation could not be identified in 37% of episodes. The most common clinical demonstrable sites of infection were mucositis (15%), acute gastroenteritis/typhlitis (12%) and upper respiratory tract infections (11%) ( Table 3) .
Adverse events
In 40 of the 100 episodes of FN, !1 AE occurred [33 MDIs, 10 RCPs and 9 SMCs (2 ALTE; 4 ICU admissions; 3 deaths)]. Radiologically confirmed pneumonia RCPs occurred in 10 FN episodes. Twenty-nine chest radiographs were reported as abnormal.
Microbiologically defined infections
Performance of the risk assessment tool AEs were present in three FN episodes at presentation (two low risk, one high risk) and two FN episodes at reassessment (two high risk). By applying the risk assessment score and calculation [21] at reassessment, AEs were correctly predicted in 21 of 42 episodes in the high-risk group and 37 of 55 episodes in the low-risk group, thus yielding a 60% sensitivity, 65% specificity, 53% PPV and 71% NPV. When applying the score at presentation, a 51% sensitivity, 68% specificity, 55% PPV and 65% NPV were calculated (Table 4) . (16) 11 (24) 16 (24) CVC, central venous catheter; ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia..
We applied the data to risk prediction scores published by other authors [11-13, 16, 17] , but none of these scores achieved the predefined sensitivity of ! 90% [21] (Table 5) .
In a univariate analysis of the predictive performance of individual variables, total WCC at 0.5 G/L (p ¼ 0.01) and absolute monocyte count (AMC) at 0.08 G/L (p ¼ 0.05) achieved statistical significance, while temperature (p ¼ 0.02) and body mass index (p ¼ 0.03) predict an AE in multivariate analysis performed on patients without an AE known at presentation. Serum CRP in the group that developed an AE did not differ from those who did not develop and AE (p ¼ 0.42) ( Table 6 ). 
D I S C U S S I O N
This study aimed to validate a risk assessment score published by Ammann et al. [21] that could lead to the identification of patients at high risk of suffering an AE during a FN episode. In the derivation and validation of Ammann's score [21] , the predefined sensitivity was established at !90%. When the score was applied at reassessment in Ammann's cohort, it achieved a 92% sensitivity, 45% specificity, 93% NPV and 40% PPV [21] . Miedema et al. could not reach these numbers in a Dutch cohort (82% sensitivity, 57%specificity, 23% PPV, 91% NPV). He proposed Table 4 . Performance of the risk prediction score applied to the three different cohorts using the ammann rule differences in chemotherapy treatment protocols, genetic factors, microbiological environments and retrospective data collection, as reasons for the lower sensitivity. In this study, the score was applied prospectively, but yielded a 60% sensitivity, 65% specificity, 53% PPV and 71% NPV at reassessment. By applying Amman's calculation used in both of the other study models, the sensitivity increased at reassessment. This calculation however assumes that the excluded cases were correctly predicted. In our cohort, two of the three excluded cases were incorrectly predicted, resulting in a false increase in sensitivity at reassessment. When the score was applied at presentation, the model yielded a 51% sensitivity, 68% specificity, 55% PPV and 65% NPV. Miedema et al. [26] demonstrated a similar performance of the prediction score at presentation (69% sensitivity, 57% specificity, 34% PPV, 85% NPV).
One possible explanation for the difference in the performance of the prediction score might be differences between the European and South African cohorts. Our cohort included younger patients (4.7 vs. 6.9 years) [21] , more patients with solid tumours (44 vs. 26%) [21] , a higher AE rate (40 vs. 29%) [21] , more bacteraemias (24 vs. 15.8%) [21] and SMCs (9 vs. 4.9%) [21] . We reported a 30% bacteraemia rate in the high-risk population vs. 7% by Ammann et al. [21] and 29% by Miedema et al. [26] Thus, 46% of bacteraemia occurred in patients predicted as low risk, including one episode that resulted in death. Miedema et al. [26] found that almost one in every three patients (29%) with bacteraemia were incorrectly classified and in the Ammann [21] cohort two of three deaths occurred in low-risk episodes. The low sensitivity in two of the three cohorts and the high number of incorrectly classified episodes in all three cohorts limit the applicability of this prediction score outside of the derivation population.
Another explanatory factor may be the higher number of patients assessed at low risk for developing an AE (57 vs. 35%). In calculating the score, an Hb ! 9 g/dl is included as the highest weighted variable. In our cohort, the mean Hb level was 8.1 g/dl on presentation, thus contributing to a lower-risk prediction score and a higher number of low-risk patients. The lower mean Hb might be explained by the adherence to international guidelines reserving blood transfusions for patients with an Hb < 7 g/dl [27] .
Many of the FN episodes occurred in patients with advanced stage of disease (24%), relapsed malignancies (16%) and solid tumours outside the central nervous system (CNS) (46%), resulting in the use of more aggressive chemotherapy protocols causing more severe bone marrow suppression and more AEs. This supports Stones et al.'s [28] finding that advanced stage disease contributes to a poorer outcome and higher incidence of AEs. This is compounded by the restricted use of granulocyte colonystimulating factor, which is reserved for cases of severe prolonged neutropenia.
Management decisions are often based on laboratory parameters including serum CRP values and differential WCC. As demonstrated in this study and confirmed by other studies, CRP is of limited value [29] [30] [31] [32] . Total WCC and AMC achieved statistical significance in univariate analysis, however their applicability in predicting AEs where limited by the low sensitivity and specificity as individual predictors (Table 6 ). Although AMC has been used in previously defined risk prediction scores, these could not be validated [11, 12, 14] , most likely because statistical significance was reached at a lower AMC level (AMC < 0.08 G/l) than in other studies [11, 12] Another limitation was the inclusion and exclusion criteria, which could not be applied strictly, as there is variability in the definitions used by the different authors [29] [30] [31] [32] .
In conclusion, although this study did not succeed in validating the Ammann score [21] , it demonstrated the important significant association between total WCC and AMC in an AE during FN. We demonstrate that other prediction scores [11-13, 16, 17] are not useful in our patient population and that a risk prediction score should be developed for low-to middle-income countries with a high burden of infectious diseases. Finally, the study demonstrated the marked differences in patient cohorts between highincome countries vs. a low-to middle-income country. Future studies should include the development of a cost-effective model, including Procalcitonin (PCT) to assist with differentiating between high-risk and low-risk FN, as PCT has been demonstrated to be a more sensitive marker for bacterial infection [29] [30] [31] .
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